Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DesignMedix Inc.

This article was originally published in Start Up

Executive Summary

One of the key ways pathogens survive in patients receiving drug therapy for infection is by physically ridding their cells of the chemicals through molecular mechanisms known as efflux pumps. Given this role, biopharma researchers have been investigating compounds meant to act as efflux pump inhibitors and so increase the efficacy of existing antibacterial and other drugs. Count DesignMedix LLC. in that group. The start-up thinks its approach will eventually give rise to drugs that reverse resistance to fluoroquinolone antibiotics like Cipro, but the company is first working on a potential anti-malarial compound.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts